Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why does rifaximin cost 95 percent more in the U.S. than in Asia?

Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
Meds
May 28, 2025
Share
Tweet
Share

Rifaximin, a minimally absorbed antibiotic, has become a cornerstone therapy for several gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy. Despite its established use, access to rifaximin varies significantly across global markets, with cost barriers posing challenges in some regions. In contrast, in many Asian countries, the same medication is available at a fraction of the price, raising important questions about pharmaceutical pricing practices and access equity.

Using publicly available pharmacy databases, we compared the price of rifaximin 550 mg tablets across different markets. In the U.S., the average retail price for a single tablet was approximately $30 to $40, as listed on GoodRx. In comparison, prices in India, Pakistan, and China were significantly lower, averaging between $0.70 to $1.50 per tablet (Table 1). These findings highlight a price difference exceeding 95 percent between certain high-income and lower-income markets.

Several factors contribute to this disparity. In the U.S., rifaximin remains protected by multiple patents listed in the FDA’s Orange Book, delaying the introduction of generics until at least 2029. In contrast, many Asian countries implement pharmaceutical price regulations and allow earlier generic market entry, thereby reducing costs for patients.

The clinical implications of this pricing gap are substantial. High out-of-pocket costs may deter the appropriate use of rifaximin, potentially affecting outcomes in chronic conditions. Addressing these disparities through policy reforms that promote competition and price transparency could improve patient access to essential therapies.

In patients with irritable bowel syndrome with diarrhea (IBS-D), rifaximin provides a non-systemic, gut-directed treatment that has demonstrated efficacy in alleviating symptoms such as bloating and altered bowel habits. Given its well-established role in IBS-D management, equitable access to rifaximin becomes particularly important. In settings where medication cost may influence prescribing patterns or patient adherence, disparities in pricing can inadvertently limit clinical utility. Broader availability at an affordable cost could enhance symptom control, reduce the burden of disease, and allow clinicians to optimize care with confidence in both efficacy and tolerability.

In an era increasingly focused on health care value and equity, global pricing discrepancies warrant critical attention. Bridging the gap for medications such as rifaximin may serve as a model for broader pharmaceutical policy reforms aimed at improving affordability and access worldwide.

Jai Kumar is an internal medicine resident. Brian Nohomovich and Leonid Shamban are gastroenterologists.

Prev

When moisturizers trigger airport bomb alarms

May 28, 2025 Kevin 0
…
Next

"The medical board doesn't know I exist. That's the point."

May 28, 2025 Kevin 0
…

Tagged as: Gastroenterology

Post navigation

< Previous Post
When moisturizers trigger airport bomb alarms
Next Post >
"The medical board doesn't know I exist. That's the point."

ADVERTISEMENT

Related Posts

  • The cost of avoiding cost: a medical student’s perspective

    Palak Patel
  • Hospital administrators thinking about no-cost treatment which really helps patients

    John Corsino, DPT
  • Our patients matter, but at what cost to our families? 

    James A. Quinn, PA-C
  • Why the Build Back Better Act is an investment, not a cost

    Shirin Shafazand, MD
  • Medicine rewards self-sacrifice often at the cost of physician happiness

    Daniella Klebaner
  • The hidden cost of a medical career: Is it still worth it?

    Harry Severance, MD

More in Meds

  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • Most Popular

  • Past Week

    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
    • Could ECMO change where we die and how our organs are donated?

      Deepak Gupta, MD | Conditions
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Could ECMO change where we die and how our organs are donated?

      Deepak Gupta, MD | Conditions
    • Every medication error is a system failure, not a personal flaw

      Muhammad Abdullah Khan | Meds
    • From Civil War tales to iPhones: a family history in contrast

      Richard A. Lawhern, PhD | Conditions
    • Reframing self-care as required maintenance for physicians [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden dangers of over-the-counter weight-loss supplements

      STRIPED, Harvard T.H. Chan School of Public Health | Conditions
    • Implementing value-based telehealth pain management and substance misuse therapy service

      Olumuyiwa Bamgbade, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
    • Could ECMO change where we die and how our organs are donated?

      Deepak Gupta, MD | Conditions
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Could ECMO change where we die and how our organs are donated?

      Deepak Gupta, MD | Conditions
    • Every medication error is a system failure, not a personal flaw

      Muhammad Abdullah Khan | Meds
    • From Civil War tales to iPhones: a family history in contrast

      Richard A. Lawhern, PhD | Conditions
    • Reframing self-care as required maintenance for physicians [PODCAST]

      The Podcast by KevinMD | Podcast
    • The hidden dangers of over-the-counter weight-loss supplements

      STRIPED, Harvard T.H. Chan School of Public Health | Conditions
    • Implementing value-based telehealth pain management and substance misuse therapy service

      Olumuyiwa Bamgbade, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why does rifaximin cost 95 percent more in the U.S. than in Asia?
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...